Generic semaglutide gets tentative OK
The FDA granted tentative approval to an ANDA for a generic semaglutide injection, a regulatory step that does not allow immediate market entry. (hcplive.com) HCPLive noted this tentative approval is an early step toward broader affordability but stops short of permitting sale until remaining regulatory barriers are cleared. (hcplive.com)
The Food and Drug Administration has tentatively cleared the first U.S. generic version of semaglutide injection, but the drug still cannot be sold. (apotex.com) Apotex said on April 10 that the tentative approval covers its abbreviated new drug application, or ANDA, for semaglutide injection, developed with Orbicular Pharmaceutical Technologies. Apotex called it the first U.S. tentative approval for a generic Ozempic version. (apotex.com) A tentative approval means Food and Drug Administration reviewers found the application met the scientific requirements for approval, but some patent or exclusivity block still prevents final approval and launch. The agency says generic approvals and tentative approvals are tracked through Drugs@FDA and the Orange Book. (fda.gov) Semaglutide is the active ingredient in Novo Nordisk’s Ozempic and Wegovy. Ozempic is approved for adults with type 2 diabetes and also carries Food and Drug Administration-approved uses to cut major cardiovascular events and slow kidney disease progression in some patients with diabetes. (accessdata.fda.gov) Ozempic first won Food and Drug Administration approval in December 2017 as a once-weekly injection for blood sugar control in adults with type 2 diabetes. Wegovy, a higher-dose semaglutide product for chronic weight management, later added a cardiovascular-risk indication, and the agency approved a 7.2 mg Wegovy HD version on March 19, 2026. (prnewswire.com) (fda.gov) (accessdata.fda.gov) The generic filing matters because semaglutide is no longer a niche diabetes drug. It sits at the center of a much larger market for diabetes, obesity, heart risk, and kidney disease treatment, with demand strong enough that Novo Nordisk announced U.S. list-price cuts for Ozempic, Wegovy, and Rybelsus on February 24, 2026. (novonordisk-us.com) Food and Drug Administration records show “first generics” are a priority because they can create lower-cost competition, but the agency also notes an approval date does not guarantee immediate availability. That caveat is even sharper here, because Apotex has only tentative approval, not final approval. (fda.gov) Apotex said the product would be marketed in the United States once it becomes eligible for final approval. Until that happens, the first generic semaglutide remains a regulatory milestone, not a pharmacy product. (apotex.com)
